Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
08 February 2025
| Name: | IMPRESSION HEALTHCARE LIMITED (IHL) (This company subsequently changed its name and is now INCANNEX HEALTHCARE LIMITED. You should refer to that name for Status.) | |||||||||
| Date of Listing: | 23 May 2007 | |||||||||
| Subsequent Names: | ||||||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now INCANNEX HEALTHCARE LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now INCANNEX HEALTHCARE LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now INCANNEX HEALTHCARE LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| INCANNEX HEALTHCARE LIMITED | 05/07/2020 | |
| IMPRESSION HEALTHCARE LIMITED | 31/10/2016 | 06/07/2020 |
| MOUNT MAGNET SOUTH LIMITED | 03/12/2015 | 31/10/2016 |
| MOUNT MAGNET SOUTH NL | 03/12/2015 |
REGISTRY:
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
name changed to Incannex Healthcare Limited | 06/07/2020 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material supply agreement. | 09/08/2019 |
The company has officially launched its wholly owned novel cannabinoid drug discovery brand Incannex Pharmaceuticals. Incannex has engaged Linnea SA to be their supply partner for base cannabinoid materials for two of its four novel cannabinoid formulations under design - TMJ Disorder and TBI/Concussion. Incannex by Impression's four areas of cannabinoid research and imminent clinical trials include: Obstructive Sleep Apnoea, Traumatic Brain Injury (TBI)/Concussion, Temporomandibular Joint (TMJ) Disorder and Periodontitis (Gum Disease) and Gingivitis. IHL under the Incannex brand has also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions prevoiusly approved for treatment with cannabinoids under Special Access Scheme. These Incannex Oils can be sold under Australia's largest distribution network "“ Cannvalate - on a non-exclusive basis. TGA Special Access Scheme Category B Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019. | 09/08/2019 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material supply agreement. | 08/08/2019 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release by IHL of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities. | 21/05/2019 |
The company's application was heard at 10.15 am on 20 May 2019. The Federal Court has made the orders, and pursuant to these orders, any person who claims to have suffered substantial injustice or is likely to suffer substantial injustice by the making of the orders has liberty to apply to vary or to discharge the orders within 60 days from the date of this announcement and the reinstatement of the company's securities by the ASX . | 21/05/2019 |
The company has become aware that a number of share and option issues made over the past few years were, in erorr, not accompanied by the issue of a cleansing prospectus. The company has filed an application with the Federal Court of Australia seeking declaratory relief and ancillary orders under the Corporations Act to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The application will be heard by the Federal Court at 10.15 am on Monday, 20 May 2019. | 16/05/2019 |
The company has lodged a cleansing prospectus to cleanse all relevant shares and options so that subsequent trading of the company's shares and options is not subject to secondary trading restrictions. The Company is also preparing an application to the Federal Court of Australia seeking declaratory relief and ancillary orders to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The Company currently expects to file this application early in the week beginning 13 May 2019. | 10/05/2019 |
The company issues a cleansing prospectus for an offer of up to 10,000 New Shares at an issue price of $0.02 per New Share (together with one free attaching New Option for every one (1) New Share subscribed for and issued) to raise up to $200. | 10/05/2019 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities. | 08/05/2019 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release of an announcement. | 19/09/2018 |
Impression secures letter of intent and exclusivity agreement with leading US-based cannabinoid biotechnology and pharmaceutical company, AXIM Biotechnologies Incorporated. The LOI considers the opportunity for Impression to license and distribute AXIM's current and future range of cannabinoid-based products for distribution by Impression in Australia and New Zealand, subject to regulatory approval. The relationship represents Impression's commitment to innovation and disruption within the oral health sector, the healthcare sector more broadly, and affords Impression the opportunity to license innovative and exciting cannabinoid products. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids and has established a full chain of production, including extraction, purification, conversion and microencapsulation. Impression has engaged reputable Melbourne-based consulting firm, Pharmout specialising in cannabinoids to advise it on regulatory and other matters related to AXIM's products. | 19/09/2018 |
The company has executed a capital raise mandate with Alignment Capital Pty Ltd to raise a total of $2.2m by way of three separate funding initiatives: an entitlement-based Rights Issue by way of prospectus; a post-Rights Issue placement; and $750,000 via a fully subscribed converting loan offer. | 19/09/2018 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement. | 18/09/2018 |
The securities of Impression Healthcare Limited will be reinstated to quotation immediately, following the release of an announcement by the Company. | 27/02/2018 |
The company has received firm commitments to place 48,453,450 fully paid ordinary shares at $0.025 to raise $1,211,336 before costs. Placement funds will primarily be allocated to marketing and promotional activities to accelerate sales growth as the Company works towards achieving break-even and profitability. | 27/02/2018 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 26/02/2018 |
The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. | 21/11/2016 |
name changed from Mount Magnet South Limited | 31/10/2016 |
name changed to Incannex Healthcare Limited | 06/07/2020 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material supply agreement. | 09/08/2019 |
The company has officially launched its wholly owned novel cannabinoid drug discovery brand Incannex Pharmaceuticals. Incannex has engaged Linnea SA to be their supply partner for base cannabinoid materials for two of its four novel cannabinoid formulations under design - TMJ Disorder and TBI/Concussion. Incannex by Impression's four areas of cannabinoid research and imminent clinical trials include: Obstructive Sleep Apnoea, Traumatic Brain Injury (TBI)/Concussion, Temporomandibular Joint (TMJ) Disorder and Periodontitis (Gum Disease) and Gingivitis. IHL under the Incannex brand has also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions prevoiusly approved for treatment with cannabinoids under Special Access Scheme. These Incannex Oils can be sold under Australia's largest distribution network "“ Cannvalate - on a non-exclusive basis. TGA Special Access Scheme Category B Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019. | 09/08/2019 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material supply agreement. | 08/08/2019 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release by IHL of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities. | 21/05/2019 |
The company's application was heard at 10.15 am on 20 May 2019. The Federal Court has made the orders, and pursuant to these orders, any person who claims to have suffered substantial injustice or is likely to suffer substantial injustice by the making of the orders has liberty to apply to vary or to discharge the orders within 60 days from the date of this announcement and the reinstatement of the company's securities by the ASX . | 21/05/2019 |
The company has become aware that a number of share and option issues made over the past few years were, in erorr, not accompanied by the issue of a cleansing prospectus. The company has filed an application with the Federal Court of Australia seeking declaratory relief and ancillary orders under the Corporations Act to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The application will be heard by the Federal Court at 10.15 am on Monday, 20 May 2019. | 16/05/2019 |
The company has lodged a cleansing prospectus to cleanse all relevant shares and options so that subsequent trading of the company's shares and options is not subject to secondary trading restrictions. The Company is also preparing an application to the Federal Court of Australia seeking declaratory relief and ancillary orders to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The Company currently expects to file this application early in the week beginning 13 May 2019. | 10/05/2019 |
The company issues a cleansing prospectus for an offer of up to 10,000 New Shares at an issue price of $0.02 per New Share (together with one free attaching New Option for every one (1) New Share subscribed for and issued) to raise up to $200. | 10/05/2019 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities. | 08/05/2019 |
The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release of an announcement. | 19/09/2018 |
Impression secures letter of intent and exclusivity agreement with leading US-based cannabinoid biotechnology and pharmaceutical company, AXIM Biotechnologies Incorporated. The LOI considers the opportunity for Impression to license and distribute AXIM's current and future range of cannabinoid-based products for distribution by Impression in Australia and New Zealand, subject to regulatory approval. The relationship represents Impression's commitment to innovation and disruption within the oral health sector, the healthcare sector more broadly, and affords Impression the opportunity to license innovative and exciting cannabinoid products. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids and has established a full chain of production, including extraction, purification, conversion and microencapsulation. Impression has engaged reputable Melbourne-based consulting firm, Pharmout specialising in cannabinoids to advise it on regulatory and other matters related to AXIM's products. | 19/09/2018 |
The company has executed a capital raise mandate with Alignment Capital Pty Ltd to raise a total of $2.2m by way of three separate funding initiatives: an entitlement-based Rights Issue by way of prospectus; a post-Rights Issue placement; and $750,000 via a fully subscribed converting loan offer. | 19/09/2018 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement. | 18/09/2018 |
The securities of Impression Healthcare Limited will be reinstated to quotation immediately, following the release of an announcement by the Company. | 27/02/2018 |
The company has received firm commitments to place 48,453,450 fully paid ordinary shares at $0.025 to raise $1,211,336 before costs. Placement funds will primarily be allocated to marketing and promotional activities to accelerate sales growth as the Company works towards achieving break-even and profitability. | 27/02/2018 |
The securities of Impression Healthcare Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 26/02/2018 |
The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. | 21/11/2016 |
name changed from Mount Magnet South Limited | 31/10/2016 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 23/03/2018 | Alistair Blake | 35,000 | $0.033 | $1,140 | |
| 04/12/2017 | Kelvin Smith | 90,000 | $0.021 | $1,879 | |
| 02/06/2017 | Alistair Blake | 25,691 | $0.041 | $1,048 | |
| 24/05/2017 | Alistair Blake | 34,466 | $0.056 | $1,916 | |
| 24/05/2017 | Kelvin Smith | 40,000 | $0.052 | $2,100 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Troy Valentine | Non Exec Chairman | 13/12/2017 |
| Joel Latham | Managing Director, CEO | 19/07/2018 |
| Peter Widdows | Non Exec Director | 01/03/2018 |
| Sud Agarwal | Non Exec Director | 25/07/2019 |
| Glenn Fowles | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Alistair Blake | Director | 20/10/2016 | 25/07/2019 |
| Matthew Weston | Managing Director, CEO | 01/02/2016 | 19/07/2018 |
| Adam Wellisch | Independent Director | 03/04/2017 | 08/05/2018 |
| John Worsfold | Director | 20/10/2016 | 12/12/2017 |
| Kelvin Smith | Director | 20/10/2016 | 12/12/2017 |
| Alec Pismiris | Non Exec Chairman | 02/08/2013 | 03/04/2017 |
| Michael Fennell | Director | 22/12/2014 | 20/10/2016 |
| David Leavy | Director | 22/12/2014 | 20/10/2016 |
| Mark Pitt | Non Exec Director | 26/10/2010 | 22/12/2014 |
| Patrick Flint | Non Exec Director | 15/04/2011 | 22/12/2014 |
| Colin Chenu | Non Exec Director | 14/09/2010 | 25/11/2013 |
| Phillip Shreeve | CFO | 01/06/2011 | 01/10/2013 |
| Reginald Gillard | Non Exec Chairman | 15/04/2011 | 02/08/2013 |
| Matthew Shackleton | Managing Director | 18/04/2008 | 10/02/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
